Management of type 1 diabetes: ADA/EASD consensus report

Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration (9:53). 0:00 – The goals of the report0:53 – The importance of psychosocial care3:35 – Are providers ready for routine use of technology?4:30 – Type […]

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Close up view of two doctors standing with their arms crossed

Speaker: Laura Coates Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis (5.10) Transcript So the KEEPsAKE 1 and 2 trials have looked at the efficacy and safety of risankizumab in patients with active psoriatic arthritis. And […]

ASCO 2021 Lung cancer: Clinical insights into key research

conference hall

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies (8:06). 00:00 – Introduction00:30 – MYLUNG study02:44 – CodeBreaK 100 trial03:52 – CHRYSALIS trial04:48 – IMpower010 trial Read transcript Hello. Thank you […]

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

Heads With Question Marks illustration

Author: Claire Barnard medwireNews: “The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether Janus kinase (JAK) inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis (RA). Introducing the topic, Elizabeth Wahl, from the University of Washington in Seattle, USA, said that […]